A unicorn is the title given to a start-up company that achieves a billion-dollar valuation. Newry-based John McEvoy was previously the Global General Counsel at a Dublin-based pharmaceutical company—a job he landed before he was 30—where he played a key role in its rapid acquisition-led growth and Nasdaq listing before it was sold last year for nearly $1.5 billion. It’s the remarkable tale of a real Irish unicorn.
He’s now planning to repeat the success with another Dublin pharma company, Poolbeg Pharma, while also setting up and growing Northern Ireland’s largest private GP services company in his spare time.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
